Amylin Chair And Lead Independent Director Voted Off The Board
This article was originally published in The Pink Sheet Daily
Executive Summary
The ouster underscores the extent to which dissident shareholders, led by Carl Icahn, have had influence as Amylin hopes to win approval of a key diabetes drug.